REG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
03/04/2025 14:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250403:nRSC5813Da&default-theme=true
RNS Number : 5813D Diaceutics PLC 03 April 2025
Diaceutics PLC
PDMR Shareholding/Share Incentive Plan and Total Voting Rights
New York, Belfast and London, 3 April 2025 - Diaceutics PLC (AIM: DXRX), a
leading technology and solutions provider to the pharma and biotech industry,
has been notified that on 1 April 2025, Global Shares Trustees (UK) Limited
(the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of
the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary
shares of £0.002 in the capital of the Company ("Shares") on behalf of
Susanne Munksted, Jordan Clark, Nick Roberts and Jillian Beggs (PDMRs), in
respect of their purchase of Shares pursuant to the Company's UK and Global
Share Incentive Plan ("the SIP Schemes") for employees. These purchases will
be made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases
with a matched share award over an equivalent number of Shares purchased by
the employee, in the proportion of 1:1.
As announced on 2 October 2023, application was made to AIM for a block
listing of 1,500,000 Shares to facilitate the admission of the Shares to
trading following the exercise of options inter alia under the SIP Schemes.
Therefore, the matched share awards for the UK PDMRs, along with those for all
other participants in the UK SIP Scheme, have been settled by the Company
issuing 6,926 Shares on 2 April 2025 to the UK Trust. The Trust will hold
these Shares on behalf of participants until they vest in accordance with the
UK Scheme rules.
Following the issue of Shares on 2 April 2025, Diaceutics has 84,798,378
Shares in issue. This figure may be used by shareholders in the Company as a
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries:
Diaceutics PLC
Ryan Keeling, Chief Executive Officer Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker) Tel: +44 (0)20 7253 8000
Simon Bridges, Andrew Potts, Harry Rees
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status Chief Precision Medicine Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Global Share Incentive Plan
("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
120.102 p 120
Conditional share award:
Price(s) Volume(s)
Nil 120
e. Date of the transaction Share purchase and Conditional share award: 1 April 2025
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Conditional share award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status Chief Data Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
120.102 p 125
Matched share award:
Price(s) Volume(s)
Nil 125
e. Date of the transaction Share purchase and Matched Share award: 1 April 2025
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Matched Share Award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status Chief Finance Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
120.102 p 125
Matched share award:
Price(s) Volume(s)
Nil 125
e. Date of the transaction Share purchase and Matched Share award: 1 April 2025
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Matched Share Award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jillian Beggs
2 Reason for notification
a. Position/Status Chief Commercial Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
120.102 p 125
Matched share award:
Price(s) Volume(s)
Nil 125
e. Date of the transaction Share purchase and Matched Share award: 1 April 2025
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Matched Share Award: Off-Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHIJMTTMTAMBJARecent news on Diaceutics
See all newsREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - Notice of Results
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - PMx Promotional Partner Contract Enhancement
Announcement